Puma Biotechnology Reports $52.4 Million Revenue and $5.9 Million Net Income for Q2 2025

Puma Biotechnology, Inc. reported a total revenue of approximately $52.4 million for the three months ended June 30, 2025, marking an increase from $47.1 million in the same period last year. This growth was driven by a rise in product revenue, net, which reached $49.2 million, up from $44.4 million, attributed to a 4% increase in the number of bottles of NERLYNX sold in the U.S. market and a higher net selling price. Royalty revenue also saw a modest increase, totaling $3.2 million compared to $2.7 million in the prior year, primarily due to enhanced international sales by sub-licensees.

In terms of expenses, the company reported a cost of sales of approximately $12.3 million for the second quarter of 2025, up from $10.7 million in the same quarter of 2024, largely due to increased royalty expenses and product costs associated with higher global sales. Selling, general, and administrative (SG&A) expenses decreased significantly to $18.0 million from $25.0 million, primarily due to reduced professional fees related to legal matters and a decrease in stock-based compensation expenses. Research and development (R&D) expenses increased to $15.5 million from $13.6 million, driven by heightened clinical trial activities for alisertib.

Puma's net income for the second quarter of 2025 was approximately $5.9 million, a notable turnaround from a net loss of $4.5 million in the same quarter of 2024. This resulted in a net income per share of $0.12, compared to a loss of $0.09 per share in the prior year. For the six months ended June 30, 2025, the company reported a net income of $8.8 million, compared to a net loss of $9.3 million for the same period in 2024.

The company’s total assets decreased to $194.9 million as of June 30, 2025, from $213.3 million at the end of 2024, primarily due to a reduction in cash and cash equivalents, which fell to $54.7 million from $69.2 million. Total liabilities also decreased significantly to $90.2 million from $121.2 million, reflecting a reduction in long-term debt as the company began repaying its obligations under the Athyrium Note Purchase Agreement. As of June 30, 2025, the company had a total stockholders' equity of $104.7 million, up from $92.1 million at the end of the previous year.

Looking ahead, Puma Biotechnology plans to continue its commercialization efforts for NERLYNX and advance the development of alisertib, which it in-licensed from Takeda Pharmaceutical Company in 2022. The company anticipates that its existing cash and cash equivalents, along with marketable securities, will be sufficient to meet its operational needs for at least the next year. However, it acknowledges the potential need for additional funding to support ongoing development and commercialization activities, particularly in light of the uncertainties surrounding market conditions and regulatory approvals.